Cited by 915Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 216 of the 218 references it cites were found in a registry or an index.

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Open access

Azzoli, Christopher G., Baker, Sherman, Temin, Sarah, Pao, William, Aliff, Timothy, Brahmer, Julie, Johnson, David H., Laskin, Janessa L., Masters, Gregory, Milton, Daniel, Nordquist, Luke, Pfister, David G., Piantadosi, Steven, Schiller, Joan H., Smith, Reily, Smith, Thomas J., Strawn, John R., Trent, David, Giaccone, Giuseppe·2009·Journal of Clinical Oncology

DOI 10.1200/jco.2009.23.5622PMC PMC2793036

Open this paper in CoChat — free account

Abstract

The purpose of this article is to provide updated recommendations for the treatment of patients with stage IV non-small-cell lung cancer. A literature search identified relevant randomized trials published since 2002. The scope of the guideline was narrowed to chemotherapy and biologic therapy. An Update Committee reviewed the literature and made updated recommendations. One hundred sixty-two publications met the inclusion criteria. Recommendations were based on treatment strategies that improve overall survival. Treatments that improve only progression-free survival prompted scrutiny of toxicity and quality of life. For first-line therapy in patients with performance status of 0 or 1, a platinum-based two-drug combination of cytotoxic drugs is recommended. Nonplatinum cytotoxic doublets are acceptable for patients with contraindications to platinum therapy. For patients with performance status of 2, a single cytotoxic drug is sufficient. Stop first-line cytotoxic chemotherapy at disease progression or after four cycles in patients who are not responding to treatment. Stop two-drug cytotoxic chemotherapy at six cycles even in patients who are responding to therapy. The first-line use of gefitinib may be recommended for patients with known epidermal growth factor receptor (EGFR) mutation; for negative or unknown EGFR mutation status, cytotoxic chemotherapy is preferred. Bevacizumab is recommended with carboplatin-paclitaxel, except for patients with certain clinical characteristics. Cetuximab is recommended with cisplatin-vinorelbine for patients with EGFR-positive tumors by immunohistochemistry. Docetaxel, erlotinib, gefitinib, or pemetrexed is recommended as second-line therapy. Erlotinib is recommended as third-line therapy for patients who have not received prior erlotinib or gefitinib. Data are insufficient to recommend the routine third-line use of cytotoxic drugs. Data are insufficient to recommend routine use of molecular markers to select chemotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2009.23.5622

Cites

216 of 216 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Self-citation
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citation
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31812f3c1a · Cited by 3,655

Show all 218 references

Research works printed but not linked: 7

10.1200/jco.2002.20.5.1335 · DOI
Lynch TJ, Presented at the 12th World Conference on Lung Cancer
Lord RV, 2002, Clin Cancer Res, 8, 2286
Mihaylova Z, 2007, J BUON, 12, 105
Langer CJ, 2004, Oncology, 18, 17
Brose MS, 2002, Cancer Res, 62, 6997
Suzuki Y, 1990, Oncogene, 5, 1037

Sorted by citations

Items 201–300 of 911

Crizotinib: A New Treatment Option for ALK -Positive Non-Small Cell Lung Cancer
O’Bryant, C. L., Wenger, S. D., Kim, M., & THOMPSON, L. A. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r002 · Cited by 47
Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib
Zhang, L., Xu, F., Wu, J., Xue, C., Zhao, Y., Jiang, W., Lin, L., Wu, X., Lu, Y., Bai, H., et al. (2012) · OncoTargets and Therapy · doi:10.2147/ott.s37289 · Cited by 46
A Randomized Phase II Study of Pemetrexed in Combination With Cisplatin or Carboplatin as First-Line Therapy for Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
Schuette, W., Gröschel, A., Sebastian, M., Andreas, S., Müller, T. R., Schneller, F., Guetz, S., Eschbach, C., Bohnet, S., Leschinger, M. I., et al. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.10.001 · Cited by 47
The Role of Prostaglandin-Endoperoxide Synthase-2 in Chemoresistance of Non-Small Cell Lung Cancer
Lin, X., Luo, W., Wang, H., Li, R.-Z., Huang, Y., Chen, L., & Wu, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00836 · Cited by 47
Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab Beyond Disease Progression in Patients with Advanced Non-Squamous Non–Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab Plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial
Gridelli, C., Bennouna, J., de Castro, J., Dingemans, A. C., Griesinger, F., Grossi, F., Rossi, A., Thatcher, N., Wong, E. K., & Langer, C. J. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.05.002 · Cited by 46
Pemetrexed in advanced non-small-cell lung cancer
Fuld, A. D., Dragnev, K. H., & Rigas, J. R. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.482560 · Cited by 46
Emerging toxicities in the treatment of non-small cell lung cancer: Ocular disorders
Agustoni, F., Platania, M., Vitali, M., Zilembo, N., Haspinger, E. R., Sinno, V., Gallucci, R., de Braud, F., & Garassino, M. C. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.05.005 · Cited by 46
Long-Term Survival of Patients with Metastatic Non-Small-Cell Lung Cancer over Five Decades
Bar, J., Urban, D., Amit, U., Appel, S., Onn, A., Margalit, O., Beller, T., Kuznetsov, T., & Lawrence, Y. R. (2021) · Journal of Oncology · doi:10.1155/2021/7836264 · Cited by 46
Transferrin-Decorated Protein-Lipid Hybrid Nanoparticle Efficiently Delivers Cisplatin and Docetaxel for Targeted Lung Cancer Treatment
Mao, K., Zhang, W., Yu, L., Yu, Y., Liu, H., & Zhang, X. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s296253 · Cited by 46
Lung cancer chemotherapy decisions in older patients: the role of patient preference and interactions with physicians
Gironés, R., Torregrosa, D., Gómez‐Codina, J., Maestu, I., Tenías, J. M., & Rosell, R. (2012) · Clinical & Translational Oncology · doi:10.1007/s12094-012-0782-6 · Cited by 46
Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS)
Yang, J. C., Wu, Y.-L. L. C., Chan, V. F., Kurnianda, J., Nakagawa, K., Saijo, N., Fukuoka, M., McWalter, G., McCormack, R., & Mok, T. S. K. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.021 · Cited by 45
A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
Kobayashi, T., Koizumi, T., Agatsuma, T., Yasuo, M., Tsushima, K., Kubo, K., Eda, S., Kuraishi, H., Koyama, S., Hachiya, T., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1831-0 · Cited by 45
Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy in Patients with Locally Advanced or Metastatic Non–Small-Cell Lung Cancer (INFORM; C-TONG 0804)
Zhao, H., Fan, Y., Ma, S., Song, X., Han, B., Cheng, Y., Huang, C., Yang, S., Liu, X., Liu, Y., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000445 · Cited by 45
Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel
Isla, D., González-Rojas, N., Nieves, D., Brosa, M., & Finnern, H. W. (2011) · Clinical & Translational Oncology · doi:10.1007/s12094-011-0683-0 · Cited by 45
Challenges to Implementation of an Epidermal Growth Factor Receptor Testing Strategy for Non–Small-Cell Lung Cancer in a Publicly Funded Health Care System
Ellis, P. M., Verma, S., Sehdev, S. R., Younus, J., & Leighl, N. B. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829f6a43 · Cited by 46
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
Yang, J. C., Kang, J. H., Mok, T. S. K., Ahn, M., Srimuninnimit, V., Lin, C., Kim, D., Tsai, C., Barraclough, H., Altuǧ, S., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.05.011 · Cited by 45
Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed–carboplatin
Tiseo, M., Giovannetti, E., Tibaldi, C., Camerini, A., Costanzo, F. D., Barbieri, F., Burgers, J. A., Vincent, A. D., Peters, G. J., Smit, E. F., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.07.009 · Cited by 45
Second-Line Therapy for Advanced NSCLC
Weiss, J. M., & Stinchcombe, T. E. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0096 · Cited by 45
Non–Small-Cell Lung Cancer in Elderly Patients: A Discussion of Treatment Options
Gajra, A., & Jatoi, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.3099 · Cited by 45
Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations
Morán, T., & Sequist, L. V. D. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1858 · Cited by 44
A Randomized Phase II Study of Gemcitabine and Carboplatin with or without Cediranib as First-Line Therapy in Advanced Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group Study N0528
Dy, G. K., Mandrekar, S. J., Nelson, G. D., Meyers, J. P., Adjei, A. A., Ross, H. J., Ansari, R., Lyss, A. P., Stella, P. J., Schild, S. E., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318274a85d · Cited by 44
Associations between TS, TTF-1, FR-α, FPGS, and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Pemetrexed Plus Carboplatin or Gemcitabine Plus Carboplatin as First-Line Chemotherapy
Grønberg, B. H., Lund‐Iversen, M., Strøm, E. H., Brustugun, O. T., & Scott, H. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182a406a3 · Cited by 44
Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not
Brule, S. Y., Al-Baimani, K. S., Jonker, H., Zhang, T., Nicholas, G. A., Goss, G. D., Laurie, S. A., & Wheatley‐Price, P. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.04.007 · Cited by 44
Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy
Nascimento, A. V., Bousbaa, H., Ferreira, D., & Sarmento, B. F. C. C. (2015) · Current Drug Targets · doi:10.2174/1389450115666140528151649 · Cited by 44
Diagnostic issues with cytopathologic interpretation of lung neoplasms displaying high‐grade basaloid or neuroendocrine morphology
Maleki, Z. (2010) · Diagnostic Cytopathology · doi:10.1002/dc.21351 · Cited by 44
Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer
Chen, Y. (2013) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2013.01.010 · Cited by 41
New Treatment Options for Lung Adenocarcinoma - in View of Molecular Background
Bittner, N., Ostoros, G., & Géczi, L. (2013) · Pathology & Oncology Research · doi:10.1007/s12253-013-9719-9 · Cited by 42
PLCG2 can exist in eccDNA and contribute to the metastasis of non-small cell lung cancer by regulating mitochondrial respiration
Yang, Y., Yang, Y., Huang, H., Song, T., Mao, S., Liu, D., Zhang, L., & Li, W. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-05755-7 · Cited by 41
Sensitization of lung cancer cells to cisplatin by β-elemene is mediated through blockade of cell cycle progression: antitumor efficacies of β-elemene and its synthetic analogs
Li, Q. Q., Wang, G., Huang, F., Li, J. M., Cuff, C. F., & Reed, E. (2013) · Medical Oncology · doi:10.1007/s12032-013-0488-9 · Cited by 41
Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer
Kusagaya, H., Inui, N., Karayama, M., Fujisawa, T., Enomoto, N., Kuroishi, S., Nakamura, Y., Matsuda, H., Yokomura, K., Koshimizu, N., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.11.009 · Cited by 41
Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial
Deplanque, G., Gervais, R., Vergnenégre, A., Falchero, L., Souquet, P.-J., Chavaillon, J.-M., Taviot, B., Fraboulet, G., Saal, H., Robert, C., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.01.019 · Cited by 41
KRAS Mutation as the Biomarker of Response to Chemotherapy and EGFR-TKIs in Patients With Advanced Non–Small Cell Lung Cancer
Campos-Parra, A. D., Zuloaga, C., Manríquez, M. E. V., Avilés, A., Borbolla-Escoboza, J. R., Cardona, A. F., Meneses, A., & Arrieta, O. G. (2013) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e318287bb23 · Cited by 41
Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status
Hsu, C.-H., Tseng, C., Chiang, C., Hsu, K.-H., Tseng, J., Chen, K., Wang, C.-L., Chen, C., Yen, S.-H., Chiu, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9338 · Cited by 41
Spindle cell and pleomorphic (“sarcomatoid”) carcinomas of the lung: an immunohistochemical analysis of 86 cases
Weissferdt, A., Kalhor, N., Canales, J. R., Fujimoto, J., Wistuba, I. I., & Moran, C. A. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.08.003 · Cited by 41
Prospective study of transarterial infusion of docetaxel and cisplatin to treat non-small-cell lung cancer in patients contraindicated for standard chemotherapy
Nakanishi, M., Yoshida, Y., & Natazuka, T. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.04.006 · Cited by 40
Percutaneous CT-Guided Radiofrequency Ablation as Supplemental Therapy After Systemic Chemotherapy for Selected Advanced Non–Small Cell Lung Cancers
Li, X., Zhao, M. D., Wang, J., Fan, W., Li, W., Pan, T., & Wu, P. (2013) · American Journal of Roentgenology · doi:10.2214/ajr.12.10511 · Cited by 41
Postprogression Survival in Patients With Advanced Non–Small-Cell Lung Cancer Who Receive Second-Line or Third-Line Chemotherapy
Hayashi, H., Okamoto, I., Taguri, M., Morita, S., & Nakagawa, K. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.09.006 · Cited by 40
Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis
Guetz, G. D., Uzzan, B., Nicolas, P., Valeyre, D., Sebbane, G., & Morère, J. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.03.007 · Cited by 40
Extending Survival of Stage IV Non-Small Cell Lung Cancer
Carnio, S., Novello, S., Mele, T., Levra, M. G., & Scagliotti, G. V. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.013 · Cited by 40
Single-agent versus combination chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer and performance status 2: A literature-based meta-analysis of randomized studies
Mörth, C., & Valachis, A. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.03.015 · Cited by 40
Clinical Outcome for EML4-ALK-Positive Patients with Advanced Non-Small-Cell Lung Cancer Treated with First-Line Platinum-Based Chemotherapy
Takeda, M., Okamoto, I., Sakai, K., Kawakami, H., Nishio, K., & Nakagawa, K. (2012) · Annals of Oncology · doi:10.1093/annonc/mds124 · Cited by 42
Photodynamic therapy for intractable bronchial lung cancer
Cai, X., Li, W., Lan-ying, Z., Wang, X., Luo, R., & Li, L.-B. (2013) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2013.08.002 · Cited by 39
Crizotinib for the treatment of non-small-cell lung cancer
Timm, A., & Kolesar, J. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120261 · Cited by 39
Differential immunohistochemical localization of desmosomal plaque‐related proteins in non‐small‐cell lung cancer
Gómez‐Morales, M., Cámara‐Pulido, M., León, M. T. M., Sánchez‐Palencia, A., Boyero, L., Gómez‐Capilla, J. A., & Fárez‐Vidal, M. E. (2013) · Histopathology · doi:10.1111/his.12126 · Cited by 39
Novel Approaches of Chemoradiotherapy in Unresectable Stage IIIA and Stage IIIB Non-Small Cell Lung Cancer
Stinchcombe, T. E., & Bogart, J. A. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0020 · Cited by 39
Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer
Pérez-Ramírez, C., Cañadas‐Garre, M., Molina‐Vila, M. Á., Robles, A. I., Faus-Dáder, M. J., & Calleja‐Hernández, M. Á. (2016) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2016.11.003 · Cited by 38
Copper-catalyzed domino reaction between 1-(2-halophenyl)methanamines and amidines or imidates for the synthesis of 2-substituted quinazolines
Omar, M. A., Conrad, J., & Beifuß, U. (2014) · Tetrahedron · doi:10.1016/j.tet.2014.02.066 · Cited by 39
Physician-patient communication of costs and financial burden of cancer and its treatment: a systematic review of clinical guidelines
Agarwal, A. A., Livingstone, A., Karikios, D. J., Stockler, M. R., Beale, P. J., & Morton, R. L. (2021) · BMC Cancer · doi:10.1186/s12885-021-08697-5 · Cited by 39
Retrospective Analysis of Third-Line and Fourth-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer
Asahina, H., Sekine, I., Horinouchi, H., Nokihara, H., Yamamoto, N., Kubota, K., & Tamura, T. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.06.008 · Cited by 39
EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study
Schuette, W., Schirmacher, P., Eberhardt, W., Fischer, J. R., von der Schulenburg, J.-M. G., Mezger, J., Schumann, C., Serke, M. H., Zaun, S., Dietel, M., et al. (2015) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-1149 · Cited by 38
Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
Pujol, J.-L., Paz-Ares, L. G., de Marinis, F., Dediu, M., Thomas, M., Bidoli, P., Corral, J., Antonio, B. S., Chouaki, N., John, W. J., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.06.007 · Cited by 39
Management of advanced lung cancer in resource-constrained settings: a perspective from India
Singh, N., Aggarwal, A. N., & Behera, D. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.119 · Cited by 39
Biomarkers with Predictive and Prognostic Function in Non–Small Cell Lung Cancer: Ready for Prime Time?
Aggarwal, C., Somaiah, N., & Simon, G. R. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0059 · Cited by 37
Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer
Besse, B., Planchard, D., Veillard, A.-S., Taillade, L., Khayat, D., Ducourtieux, M., Pignon, J., Lumbroso, J., LAFONTAINE, C. A., Mathiot, C., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.09.006 · Cited by 37
Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung cancer (NSCLC)
Reinmuth, N., Meyer, A. A., Hartwigsen, D., Schaeper, C., Huebner, G., Skock-Lober, R., Bier, A., Gerecke, U., Held, C. P., & Reck, M. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.01.001 · Cited by 37
Thymidylate synthase inhibitors for non-small cell lung cancer
Galvani, E., Peters, G. J., & Giovannetti, E. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.617742 · Cited by 36
Lung Cancer Genotype-Based Therapy and Predictive Biomarkers: Present and Future
Cagle, P. T., & Allen, T. C. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0508-ra · Cited by 36
Assembly of 4H-chromenes, imidazobenzothiazines and quinazolines via copper-catalyzed domino reactions using 2-halobenzyl tosylates as substrates
Omar, M. A., Conrad, J., & Beifuß, U. (2014) · Tetrahedron · doi:10.1016/j.tet.2014.06.071 · Cited by 36
Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer--data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002)
Miyauchi, E., Inoue, A., KOBAYASHI, K. P., Maemondo, M., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Saijo, Y., Yoshizawa, H., et al. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv054 · Cited by 36
Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: A subanalysis of the phase III, randomized SATURN study
Wu, Y.-L. L. C., Kim, J.-H., Park, K., Zaatar, A., Klingelschmitt, G., & Ng, C. S. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.03.012 · Cited by 36
Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer
Papadimitrakopoulou, V. A., Soria, J., Jappe, A., Jehl, V., Klimovsky, J., & Johnson, B. E. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182614835 · Cited by 36
Pemetrexed Therapy in Elderly Patients With Good Performance Status: Analysis of Two Phase III Trials of Patients With Nonsquamous Non–Small-Cell Lung Cancer
Gridelli, C., Brodowicz, T., Langer, C. J., Peterson, P. M., Islam, M., Guba, S. C., Moore, P., Visseren‐Grul, C., & Scagliotti, G. V. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.12.002 · Cited by 36
Phase I Study of Pazopanib in Combination with Paclitaxel and Carboplatin Given Every 21 Days in Patients with Advanced Solid Tumors
Burris, H. A., Dowlati, A., Moss, R. A., Infante, J. R., Jones, S. F., Spigel, D. R., Levinson, K. T., Lindquist, D., Gainer, S. D., Dar, M. M., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0997 · Cited by 37
Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer
Lazzari, C., Bulotta, A., Ducceschi, M., Viganò, M. G., Brioschi, E., Corti, F., Gianni, L., & Gregorc, V. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00004 · Cited by 37
Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients
Pérez-Ramírez, C., Cañadas‐Garre, M., Alnatsha, A., Villar, E., Valdivia-Bautista, J., Faus-Dáder, M. J., & Calleja‐Hernández, M. Á. (2018) · The Pharmacogenomics Journal · doi:10.1038/s41397-018-0014-8 · Cited by 37
Cost Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer
Bongers, M. L., Coupé, V. M. H., Jansma, E. P., Smit, E. F., & Groot, C. A. U. (2011) · PharmacoEconomics · doi:10.2165/11595000-000000000-00000 · Cited by 35
Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations
Asami, K., Okuma, T., Hirashima, T., Kawahara, M., Atagi, S., Kawaguchi, T., Okishio, K., Omachi, N., & Takeuchi, N. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.11.022 · Cited by 35
Cost-Effectiveness of Second-Line Chemotherapy for Non-small Cell Lung Cancer: An Economic, Randomized, Prospective, Multicenter Phase III Trial Comparing Docetaxel and Pemetrexed: The GFPC 05-06 Study
Vergnenégre, A., Corre, R., Berard, H., Paillotin, D., Dujon, C., Robinet, G., Créquit, J., Bota, S., Thomas, P. A., & CHOUAID, C. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318200f4c1 · Cited by 35
A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer
Stinchcombe, T. E., Peterman, A. H., Lee, C. B., Moore, D. T., Beaumont, J. L., Bradford, D. S., BAKRI, K. M., Taylor, M., Crane, J. M., Schwartz, G. H., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182210430 · Cited by 35
SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A
Hung, M., Wang, C., Chen, Y., Chu, P., Hsiao, Y., Tai, W., Chao, T.-T., Yu, H.-C., Shiau, C., & Chen, K. (2015) · Oncotarget · doi:10.18632/oncotarget.6313 · Cited by 35
LZ-106, a novel analog of enoxacin, inducing apoptosis via activation of ROS-dependent DNA damage response in NSCLCs
Yang, L., Yuan, Y., Fu, C., Xu, X., Zhou, J., Wang, S., Kong, L., Li, Z., Guo, Q., & Wei, L. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.03.007 · Cited by 35
Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer
Wu, Y.-L. L. C., Lü, S., Cheng, Y., Zhou, C., Wang, M., Qin, S., Lü, Y., Zhang, Y., Zhu, Y., Song, X., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.07.007 · Cited by 35
Maintenance Therapy in Advanced Non-small Cell Lung Cancer: Current Status and Future Implications
Stinchcombe, T. E., & Socinski, M. A. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318200f9c5 · Cited by 34
RETRACTED ARTICLE: Lidocaine alleviates cytotoxicity-resistance in lung cancer A549/DDP cells via down-regulation of miR-21
Yang, Q., Zhang, Z., Xu, H., & Ma, C. (2019) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-018-3490-x · Cited by 34
Retracted
Synergistic killing effect of paclitaxel and honokiol in non-small cell lung cancer cells through paraptosis induction
Li, X., Ren, J., Wang, Y., Su, J., Zhu, Y., Chen, C.-G., Long, W., Jiang, Q., & Li, J. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00557-x · Cited by 34
Update on Taxanes in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Socinski, M. A. (2014) · Current Oncology · doi:10.3747/co.21.1997 · Cited by 34
Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer
He, J., Shen, J., Yang, C., Jiang, L., Liang, W., Shi, X., Xu, X., & He, J. (2015) · Medicine · doi:10.1097/md.0000000000000903 · Cited by 33
Reflex Testing for Epidermal Growth Factor Receptor Mutation and Anaplastic Lymphoma Kinase Fluorescence In Situ Hybridization in Non–Small Cell Lung Cancer
Mino-Kenudson, M. A., & Mark, E. J. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2011-0029-rai.1 · Cited by 33
Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial
Gervais, R., Robinet, G., Clément-Duchêne, C., Denis, F., Kouri, C. E., Martin, P., Chouaki, N., Bourayou, N., & Morère, J. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.01.008 · Cited by 33
Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group
Fløtten, Ø., Grønberg, B. H., Bremnes, R. M., Amundsen, T., Sundstrøm, S. H., Rolke, H. B., Hornslien, K., Wentzel‐Larsen, T., Aasebø, U., & von Plessen, C. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.284 · Cited by 33
Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease.
Okuda, K., Hirose, T., Oki, Y., Murata, Y., Kusumoto, S., Sugiyama, T., Ishida, H., Shirai, T., Nakashima, M., Yamaoka, T., et al. (2012) · PubMed · Cited by 33
Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients
Pérez-Ramírez, C., Cañadas-Garre, M., Alnatsha, A., Villar, E., Delgado, J. R., Faus-Dáder, M. J., & Calleja-Hernández, M. Ÿ. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.002 · Cited by 33
Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer
Banna, G. L., Anile, G., Russo, G. I., Vigneri, P. G., Castaing, M., Nicolosi, M., Strano, S., Gieri, S., Spina, R., Patanè, D., et al. (2016) · Oncology · doi:10.1159/000448005 · Cited by 33
Mind-mapping for lung cancer: Towards a personalized therapeutics approach
Mollberg, N. M., Surati, M., Demchuk, C., Fathi, R., Salama, A. K. S., Husain, A. N., Hensing, T. A., & Salgia, R. (2011) · Advances in Therapy · doi:10.1007/s12325-010-0103-9 · Cited by 34
Large-cell carcinoma of the lung
Sholl, L. M. (2014) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000068 · Cited by 33
A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy
Ahn, J. S., Lee, K. H., Sun, J., Park, K., Kang, E., Cho, E. K., Lee, K. H., Kim, S., Lee, G., Kang, J., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.027 · Cited by 33
Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer
Karayama, M., Inui, N., Fujisawa, T., Enomoto, N., Nakamura, Y., Kuroishi, S., Yokomura, K., Koshimizu, N., Sato, M., Toyoshima, M., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.01.013 · Cited by 33
CDKN1A upregulation and cisplatin‑pemetrexed resistance in non‑small cell lung cancer cells
Zamagni, A., Pasini, A., Pirini, F., Ravaioli, S., Giordano, E., Tesei, A., Calistri, D., Ulivi, P., Fabbri, F., Foca, F., et al. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5024 · Cited by 32
Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis
Milione, M., Maisonneuve, P., Grillo, F., Mangogna, A., Centonze, G., Prinzi, N., Pusceddu, S., Garzone, G., Cattaneo, L., Busico, A., et al. (2020) · Neuroendocrinology · doi:10.1159/000508376 · Cited by 32
A comprehensive immunohistochemistry algorithm for the histological subtyping of small biopsies obtained from non‐small cell lung cancers
Koh, J., Go, H., Kim, M., Jeon, Y. K., Chung, J.-H., & Chung, D. H. (2014) · Histopathology · doi:10.1111/his.12507 · Cited by 32
Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas
Rolland, D., Basrur, V., Conlon, K., Wolfe, T., Fermin, D., Nesvizhskii, A. I., Lim, M. S., & Elenitoba-Johnson, K. S. J. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.01.036 · Cited by 31
Cost-Effectiveness of Continuation Maintenance Pemetrexed After Cisplatin and Pemetrexed Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Estimates From the Perspective of the Chinese Health Care System
Zeng, X., Peng, L., Li, J., Chen, G., Tan, C., Wang, S., Wan, X., Ouyang, L., & Zhao, Z. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.12.013 · Cited by 32
Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group Study
Tateishi, K., Ichiyama, T., Hirai, K., Agatsuma, T., Koyama, S., Hachiya, T., Morozumi, N., Shiina, T., & Koizumi, T. (2013) · Medical Oncology · doi:10.1007/s12032-012-0450-2 · Cited by 32
Characteristics and outcome of patients with second primary lung cancer
Reinmuth, N., Stumpf, A., Stumpf, P., Muley, T., Kobinger, S., Hoffmann, H., Herth, F. J. F., Schnabel, P. A., Warth, A., Bischoff, H. G., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00022512 · Cited by 31
The Incidence of Hyponatraemia and Its Effect on the ECOG Performance Status among Lung Cancer Patients
Saha, K. (2013) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2013/5900.3225 · Cited by 31
Activation of sphingosine 1-phosphate receptor 2 attenuates chemotherapy-induced neuropathy
Wang, W., Xiang, P., Chew, W. S., Torta, F. T., Bandla, A., López, V., Seow, W. L., Lam, B. W. S., Chang, J. K., Wong, P., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011699 · Cited by 31
Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers
Karve, S. J., Price, G. L., Davis, K. L., Pohl, G. M., Smyth, E. N., & Bowman, L. (2014) · BMC Health Services Research · doi:10.1186/s12913-014-0555-8 · Cited by 31
Smoking History as a Predictive Factor of Treatment Response in Advanced Non–Small-Cell Lung Cancer: A Systematic Review
Mitchell, P. L. R., Mok, T. S. K., Barraclough, H., Strizek, A., Lew, R. A., & Kooten, M. V. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.08.003 · Cited by 31
BAP1 is a good prognostic factor in advanced non-small cell lung cancer
Fan, L., Tang, L., Yue, L., Yang, Y., Gao, Z., & Shen, Z. (2012) · Clinical and investigative medicine · doi:10.25011/cim.v35i4.17146 · Cited by 31
Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe
Ramlau, R., Čufer, T., Berzinec, P., Dziadziuszko, R., Olszewski, W., Popper, H., Bajčić, P., Dusšk, L., Zbožínková, Z., & Pirker, R. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000621 · Cited by 31

Authors: Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., Nordquist, L., Pfister, D. G., Piantadosi, S., Schiller, J. H., Smith, R., Smith, T. J., Strawn, J. R., Trent, D., & Giaccone, G.
Affiliations: American Society of Clinical Oncology (US)
ORCID: Azzoli, Christopher G.
Temin, Sarah
Pao, William
Brahmer, Julie
Johnson, David H.
Masters, Gregory
Pfister, David G.
Piantadosi, Steven
Schiller, Joan H.
Smith, Thomas J.
Giaccone, Giuseppe
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2009-12-20
Volume: 27
Issue: 36
Pages: 6251-6266
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2009.23.5622
PMC: PMC2793036
OpenAlex: W2119366998
Cited by: 915
References: 218
Citations by year: 2026: 6 · 2025: 4 · 2024: 9 · 2023: 8 · 2022: 12 · 2021: 25 · 2020: 21 · 2019: 33 · 2018: 38 · 2017: 38 · 2016: 67 · 2015: 89 · 2014: 111 · 2013: 128 · 2012: 119
FWCI: 90.05
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: stage IV non-small cell lung cancer, chemotherapy, first-line therapy, second-line therapy, third-line therapy, gefitinib, erlotinib, bevacizumab, carboplatin-paclitaxel, cetuximab, docetaxel, EGFR mutation, platinum-based doublets, overall survival, progression-free survival, treatment toxicity
MeSH terms: Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Neoplasm Staging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks